Pulmatrix is a clinical-stage biotechnology company developing inhaled therapeutic products for respiratory and systemic diseases. The company's core technology platform, iSPERSE, is an engineered dry powder delivery system designed to enable pulmonary administration of both small and large molecule drugs for local or systemic therapeutic effects. This platform approach positions the company to address multiple disease areas through a single delivery mechanism.
The company's pipeline includes PUR1800, a narrow spectrum kinase inhibitor that completed Phase 1b clinical trials for acute exacerbations of chronic obstructive pulmonary disease; PUR1900 for allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis patients; and PUR3100, an iSPERSE formulation of dihydroergotamine in Phase 1 for acute migraine treatment. Pulmatrix also maintains a license agreement with RespiVert Ltd. providing access to a portfolio of kinase inhibitor compounds. The company currently operates with a minimal workforce of two full-time employees and is headquartered in Framingham, Massachusetts.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.41 | $-1.41 | +46.2% | |
| 2024 | $-2.62 | $-2.62 | +32.3% | |
| 2023 | $-3.87 | $-3.87 | +29.1% | |
| 2022 | — | $-5.46 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001493152-26-008130 | SEC ↗ |
| 2024-12-31 | 2025-03-21 | 0001493152-25-011084 | SEC ↗ |
| 2023-12-31 | 2024-03-28 | 0001493152-24-011630 | SEC ↗ |
| 2022-12-31 | 2023-03-30 | 0001493152-23-009609 | SEC ↗ |
| 2021-12-31 | 2022-03-29 | 0001493152-22-007957 | SEC ↗ |
| 2020-12-31 | 2021-03-23 | 0001493152-21-006602 | SEC ↗ |
| 2019-12-31 | 2020-03-26 | 0001193125-20-086168 | SEC ↗ |
| 2018-12-31 | 2019-02-19 | 0001193125-19-043624 | SEC ↗ |
| 2017-12-31 | 2018-03-13 | 0001193125-18-080793 | SEC ↗ |
| 2016-12-31 | 2017-03-10 | 0001193125-17-077912 | SEC ↗ |
| 2015-12-31 | 2016-03-10 | 0001193125-16-499264 | SEC ↗ |
| 2015-03-31 | 2015-06-10 | 0001144204-15-036361 | SEC ↗ |
| 2014-03-31 | 2014-06-30 | 0001144204-14-040451 | SEC ↗ |